Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01769209 · ClinicalTrials.gov registry record · Phase 2
Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT01769209: Completed Phase 2 study, sponsored by Stanford University.
NCT01769209 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01769209, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study evaluates the value of bortezomib in combination with specified chemotherapies for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Dexamethasone
- DRUG Bortezomib
- DRUG PEG-Asparaginase
- DRUG Vincristine sulfate
- DRUG Doxorubicin hydrochloride (HCl)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-03 |
| Est. Completion | 2017-07-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01769209
The ClinicalTrials.gov registry entry for NCT01769209 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Dexamethasone is the first listed.
NCT01769209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01769209 about?
NCT01769209 is a clinical study titled "Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia". This study evaluates the value of bortezomib in combination with specified chemotherapies for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01769209?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2013-03. Estimated completion is 2017-07-04.
What interventions are being tested in trial NCT01769209?
The interventions under investigation include: Dexamethasone (DRUG), Bortezomib (DRUG), PEG-Asparaginase (DRUG), Vincristine sulfate (DRUG), Doxorubicin hydrochloride (HCl) (DRUG).
Who is sponsoring clinical trial NCT01769209?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.